Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasvolsky, Oren, Leader, Avi, Iakobishvili, Zaza, Wasserstrum, Yishay, Kornowski, Ran, Raanani, Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837152/
https://www.ncbi.nlm.nih.gov/pubmed/33530148
http://dx.doi.org/10.1186/s40959-015-0008-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837152/
https://www.ncbi.nlm.nih.gov/pubmed/33530148
http://dx.doi.org/10.1186/s40959-015-0008-5

Ejemplares similares